The quarter beat published financial expectations, but the revenue upside was largely known before this release. Net loss per share was $0.62, better than the published consensus loss of about $0.72, while collaboration revenue was $65.0 million versus roughly $32 million expected. The entire revenue figure came from a previously announced $45 million Gilead option exercise and $20 million Sanofi development milestone—not recurring product sales. (Consolidated Statements of Operations and Comprehensive Loss; Financial Results)
| Metric | Q2 2026 actual | Q2 2025 | Expectation / context |
|---|---|---|---|
| Collaboration revenue | $65.0M | $11.5M | Published consensus: roughly $32M; entirely Gilead/Sanofi milestone revenue (Financial Results) |
| Net loss per share | $(0.62) | $(0.95) | Published consensus: roughly $(0.72) (Consolidated Statements of Operations and Comprehensive Loss) |
| R&D expense | $119.5M | $78.4M | Higher spending on KT-621, platform, and discovery programs (Financial Results) |
| Cash, equivalents and marketable securities | $1.505B | $1.619B at Dec. 31, 2025 | Runway reiterated into 2029 (Consolidated Balance Sheets; Financial Results) |
The clinically important timing improvement is not new information in this 8-K. KT-621's atopic-dermatitis Phase 2b enrollment finished nearly six months early, moving topline data to year-end 2026 from prior mid-2027 guidance; however, Kymera announced that acceleration in June. This filing reiterates it rather than adding efficacy or safety results, so the central clinical catalyst and its risk remain unchanged. (STAT6 Degrader Program)
Cash remains the practical offset to sharply higher development spending. R&D rose 52% year over year to $119.5 million as Kymera funds KT-621 and earlier programs, but the company still reported $1.5 billion of liquidity and maintained its runway statement into 2029. The $20 million Sanofi payment was recognized in Q2 but received in Q3, explaining the balance-sheet receivable rather than adding to June-end cash. (Financial Results; Consolidated Balance Sheets)
Net read: a modest expectation beat, not a new fundamental reset. The reported numbers are better than consensus, but they reflect partner payments already disclosed in April and June. With no new clinical data, no further pull-forward beyond the June update, and no change to the year-end KT-621 readout, this filing mainly confirms execution and funding rather than materially changing the program's near-term thesis. (Partnered Programs; STAT6 Degrader Program)
Read the original 8-K on SEC EDGAR ↗